Vimovo is owned by Horizon.
Vimovo contains Esomeprazole Magnesium; Naproxen.
Vimovo has a total of 9 drug patents out of which 6 drug patents have expired.
Expired drug patents of Vimovo are:
Vimovo was authorised for market use on 30 April, 2010.
Vimovo is available in tablet, delayed release;oral dosage forms.
Vimovo can be used as risk-reduction of nsaid-associated gastric ulcers in patients also taking low dose aspirin, risk-reduction of nsaid-associated gastric ulcer in patients requiring nsaid treatment, relief of signs and symptoms of arthritis and risk-reduction of nsaid-associated gastric ulcer, risk-reduction of nsaid gastric ulcer in patients requiring chronic nsaid treatment.
The generics of Vimovo are possible to be released after 17 October, 2031.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8858996 | HORIZON | Pharmaceutical compositions for the coordinated delivery of NSAIDS |
May, 2022
(9 months ago) | |
US8852636 | HORIZON | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
May, 2022
(9 months ago) | |
US9161920 | HORIZON | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
May, 2022
(9 months ago) | |
US9198888 | HORIZON | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
May, 2022
(9 months ago) | |
US9707181 | HORIZON | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
May, 2022
(9 months ago) | |
US9345695 | HORIZON | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
May, 2022
(9 months ago) | |
US9393208 | HORIZON | Method for delivering a pharmaceutical composition to patient in need thereof |
Sep, 2029
(6 years from now) | |
US9220698 | HORIZON | Method for delivering a pharmaceutical composition to patient in need thereof |
Mar, 2031
(7 years from now) | |
US8945621 | HORIZON | Method for treating a patient at risk for developing an NSAID-associated ulcer |
Oct, 2031
(8 years from now) |
Drugs and Companies using ESOMEPRAZOLE MAGNESIUM; NAPROXEN ingredient
Market Authorisation Date: 30 April, 2010
Treatment: Relief of signs and symptoms of arthritis and risk-reduction of nsaid-associated gastric ulcer; Risk-reduction of nsaid gastric ulcer in patients requiring chronic nsaid treatment; Risk-reduction of n...
Dosage: TABLET, DELAYED RELEASE;ORAL
26
United States
5
Australia
5
European Union
3
Mexico
3
Japan
3
EA
3
Canada
2
Morocco
2
Norway
2
Brazil
2
Korea, Republic of
2
China
2
Tunisia
1
Israel
1
South Africa
1
Denmark
1
Austria
1
Belgium
1
Germany
1
Singapore
1
Sweden
1
Portugal
1
Cyprus
1
Spain
1
United Kingdom
1
Luxembourg
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic